PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

Trastuzumab is the only HER2/neu-directed therapy to have received Food and Drug Administration approval for the treatment of patients with metastatic breast cancer. The efficacy of trastuzumab depends on the HER2/neu status of the tumour and the patient's prior treatment, but even when patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, T, Doihara, H, Kawasaki, K, Takabatake, D, Takahashi, H, Washio, K, Tsukuda, K, Ogasawara, Y, Shimizu, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361109/
https://www.ncbi.nlm.nih.gov/pubmed/16404430
http://dx.doi.org/10.1038/sj.bjc.6602926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361109/
https://www.ncbi.nlm.nih.gov/pubmed/16404430
http://dx.doi.org/10.1038/sj.bjc.6602926

Ejemplares similares